The recurrent missense mutation p.(Arg367Trp) in YARS1 causes a distinct neurodevelopmental phenotype

Luisa Averdunk1,2 · Heinrich Sticht3 · Harald Surowy1 · Hermann-Josef Lüdecke3 · Margarete Koch-Hogrebe4 · Hessa S. Alsafi5 · Kimia Kahrizi6 · Hamad Alzaidan5 · Bashayer S. Alawam5 · Mohamed Tohary5 · Cornelia Kraus7 · Sabine Endele7 · Erin Wadman8 · Julie D. Kaplan8 · Stephanie Efthymiou9 · Hossein Najmabadi5 · André Reis7 · Fowzan S. Alkuraya5 · Dagmar Wieczorek1

Received: 12 March 2021 / Revised: 21 July 2021 / Accepted: 30 July 2021 / Published online: 18 September 2021
© The Author(s) 2021

Abstract
Pathogenic variants in aminoacyl-tRNA synthetases (ARS1) cause a diverse spectrum of autosomal recessive disorders. Tyrosyl tRNA synthetase (TyrRS) is encoded by YARS1 (cytosolic, OMIM*603,623) and is responsible of coupling tyrosine to its specific tRNA. Next to the enzymatic domain, TyrRS has two additional functional domains (N-Terminal TyrRSMini and C-terminal EMAP-II-like domain) which confer cytokine-like functions. Mutations in YARS1 have been associated with autosomal-dominant Charcot-Marie-Tooth (CMT) neuropathy type C and a heterogenous group of autosomal recessive, multisystem diseases. We identified 12 individuals from 6 families with the recurrent homozygous missense variant c.1099C>T;p.(Arg367Trp) (NM_003680.3) in YARS1. This variant causes a multisystem disorder with developmental delay, microcephaly, failure to thrive, short stature, muscular hypotonia, ataxia, brain anomalies, microcytic anemia, hepatomegaly, and hypothyroidism. In silico analyses show that the p.(Arg367Trp) does not affect the catalytic domain responsible of enzymatic coupling, but destabilizes the cytokine-like C-terminal domain. The phenotype associated with p.(Arg367Trp) is distinct from the other biallelic pathogenic variants that reside in different functional domains of TyrRS which all show some common, but also divergent clinical signs [(e.g., p.(Phe269Ser)—retinal anomalies, p.(Pro213Leu)/p.(Gly525Arg)—mild ID, p.(Pro167Thr)—high fatality)]. The diverse clinical spectrum of ARS1-associated disorders is related to mutations affecting the various non-canonical domains of ARS1, and impaired protein translation is likely not the exclusive disease-causing mechanism of YARS1- and ARS1-associated neurodevelopmental disorders.

Key messages
- The missense variant p.(Arg367Trp) in YARS1 causes a distinct multisystem disorder.
- p.(Arg367Trp) affects a non-canonical domain with cytokine-like functions.
- Phenotypic heterogeneity associates with the different affected YARS1 domains.
- Impaired protein translation is likely not the exclusive mechanism of ARS1-associated disorders.

Keywords Functional protein domains · Phenotypic heterogeneity · Aminoacyl-tRNA synthetases (ARS1) · Novel disease genes · Neurodevelopmental disorders · Multisystem diseases

Introduction
Pathogenic variants in aminoacyl-tRNA synthetases (ARS1) have been implicated in neurodevelopmental disorders and multisystem diseases affecting many different tissues. Aminoacyl-tRNA synthetases catalyze the attachment of specific amino acids to their corresponding tRNA. ARS1 proteins are cytoplasmic proteins, whereas ARS2 proteins act in the mitochondria. YARS1 encodes the cytosolic tyrosyl-tRNA synthetase (TyrRS), that is, responsible of linking tyrosine to its specific tRNA and requires homodimerization for enzyme activity.

Already in 1999, it was shown that apart from its enzymatic function, TyrRS has acquired at least two additional functional motifs in higher eukaryotes during evolution [1]. The N-terminal ELR motif was identified to play an important role as an interleukin-8 (IL-8)-like cytokine by binding to CXCR1, and to induce angiogenesis and thrombopoiesis [2, 3]. The C-terminal endothelial monocyte-activating polypeptide II (EMAP-II)-like domain exerts...
cytokine functions, e.g., by inducing the migration of leukocytes (macrophages, granulocytes) and the expression and release of tumor necrosis factor-α (TNF-α), tissue factor or myeloperoxidase [1, 4, 5]. While the cytokine-like functions of TyrRS are inactive in the dimeric full-length protein, secretion, dissociation into monomers and cleavage by proteases (elastase or plasmin) activates the secondary functions of the N- and C-terminal fragments [6].

The spectrum of diseases associated with ARS1 is very broad. Pathogenic variants in all ARS1 coding genes have been implicated in autosomal recessive disorders, many of them presenting as early onset, severe multisystem diseases, while six of these (GARS, AARS1, KARS1, HARS1, MARS1, YARS1) have also been implicated in autosomal-dominant, late-onset neuropathies [7–13].

Heterozygous pathogenic variants in YARS1 have been first identified to cause autosomal-dominant Charcot-Marie-Tooth (CMT) neuropathy type C (OMIM #608,323) [7, 10]. Recently, five different biallelic variants in YARS1 have been published to cause autosomal recessive disorders [14–18]. However, the disorders attributed to biallelic pathogenic variants in YARS1 in these five families are heterogeneous ranging from severe intellectual disability (ID) with infant mortality to milder conditions without ID primarily affecting the sensory system [17].

The goal of this study was to delineate the clinical phenotypes associated with biallelic pathogenic variants in YARS1 in order to improve disease recognition and health surveillance.

Via GeneMatcher and international collaborations, we identified and characterized a set of twelve patients with developmental delay and multisystem diseases that were all homozygous for the specific variant NM_003680.3:c.1099C>T, p.(Arg367Trp). We review all individuals with biallelic YARS1 pathogenic variants reported in the literature and search for the common denominator and major discrepancies in clinical presentation of distinct YARS1 variations.

By in silico analysis, we study the predicted effect of p.(Arg367Trp) on the protein structure and stability and discuss the impact on the canonical enzyme function of TyrRS and on the non-canonical, secondary functions of TyrRS.

We suggest that an impaired protein synthesis is not the primary mechanism underlying YARS1-(and ARS1-) associated disorders, but that they arise from defective non-canonical, secondary functional domains.

Identification of biallelic YARS1 pathogenic variants by exome sequencing and Sanger sequencing

Genetic testing preceding exome sequencing including cytogenetic and chromosomal microarray analyses did not reveal any causative genetic aberrations. Exome sequencing was performed according to standard methods (Supplementary material). Sanger sequencing was performed for confirmation of reported variants.

Review of published individuals

A literature search was performed in PubMed (search terms YARS, tyrosyl-tRNA synthetase deficiency). All clinical details and laboratory results were retrieved from the manuscripts, categorized and summarized.

In silico variant prediction, protein modeling, and structural prediction

Effects of the p.(Arg367Trp) variant were predicted using PROVEAN, SIFT, PolyPhen-2, and MutationTaster [19]. Structural analysis of the p.(Arg367Trp) variant was based on a crystal structure of the C-terminal domain of human TyrRS (PDB code:1NTG) [20]. The effect of the pathogenic variant was modeled using Missense3D [21]. RasMol was used for visualization [22]. Multiple species protein alignment was done with Uniprot [23]. The impact of published recessive variants on protein structure and stability was analyzed using the VIPUR algorithm [24]. A VIPUR score > 0.5 indicates a critical destabilization of protein structure.

Materials and methods

Patient recruitment and clinical assessment

The study was performed according to the Declaration of Helsinki. The study was approved by the institutional ethical review boards (King Faisal Specialist Hospital and Research Center; Ref. No # 2,121,053 and 2,080,006; University Hospital Erlangen Ref. No. 253_15B). Patients with multisystem diseases and biallelic pathogenic variants in YARS1 were recruited for the study. Ten of the 12 individuals with homozygous p.(Arg367Trp) YARS1 variants were identified newly in-hospital or by international partners. Written informed consent for publishing of clinical, genetic data, and photographs was obtained from the patients and their legal guardians. Two (J:II-1 and K:II-2) of the 12 individuals had been identified within a large cohort of consanguineous families with ID before and clinical data that had not been published were provided after additional follow-up investigations and in depth review of medical records [15]. Clinical and laboratory findings of all patients were centrally reviewed, categorized and summarized.
Results

Identification and in silico analysis of YARS1 c.1099C>T, p.(Arg367Trp)

In all included patients, homozygosity of the variant NM_003680.3(YARS1):c.1099C>T, p.(Arg367Trp) ([GRCH38/hg38] chr1:g.32,781,089G>A) in exon 10 of YARS1 was identified by exome sequencing. No other likely pathogenic variant of clinical significance was identified in any patient. The haplotypes of the individuals originating from Saudi Arabia (C-I) differs from the haplotypes of individuals A+B (from Turkey) and L (from Puerto Rico) (Supplementary Table S1). While this finding does not rule out a founder effect common to the Saudi patients (C-I), it is less likely that also p.(Arg367Trp) of A+B and L traces back to the same, shared founder. The homozygous variant was absent from internal control databases but reported in dbSNP (rs376054085). The allele frequency in the gnomAD v2.1.1 population database is 3.89 x 10^-5, with 11 known heterozygotes among 141,403 individuals, of which 10 have Latino and 1 has South Asian ancestry. The variant affects an arginine residue at position 367 (Arg367) of human TyrRS, in the C-terminal EMAP-II-like domain (residues 364–528) and is located three amino acids away from the tRNA anticonodon-binding domain (Fig. 1A). In silico tools predict deleterious effects on protein structure and function (prediction scores: PROVEAN: −5.642, SIFT: 0.03, PolyPhen-2: HumDiv 1.000/HumVar 0.953, MutationTaster: “disease causing”). Arginine in position 367 is highly conserved in mammals and down to Drosophila melanogaster, but not in Xenopus tropicalis (western clawed frog) and Caenorhabditis elegans (Fig. 1E). Given the PS4, PP1, PP2, and PP3 ACMG/AMP criteria being fulfilled and the consistent phenotype in 12 individuals of 6 families, the p.(Arg367Trp) in YARS1 was considered to be the causative genetic alteration in the patients [25].

In silico protein modeling and structural prediction

The p.(Arg367Trp) variant is located in the C-terminal EMAP-II-like domain (residues 364–528) of TyrRS. In silico analysis of the wildtype structure reveals that arginine in position 367 (Arg367) forms tight electrostatic interactions with the oppositely charged aspartic acid in position 478 (Asp478), thereby stabilizing the domain structure (Fig. 1C). In the mutant, the bulkier and uncharged tryptophan (Trp367) cannot form this interaction resulting in a rearrangement of the sidechains and a reduced domain stability (Fig. 1D). The site of the p.(Arg367Trp) exchange is in the immediate vicinity of a hexapeptide stretch (residues 371–377) that is critical for the cytokine activity of the EMAP-II domain of TyrRS. [1] Amino acid alignment of the C-terminal EMAP-II-like domain of YARS1 and the aminoacyl-tRNA synthetase complex interacting multifunctional protein 1 (AIMP1) shows that their corresponding residues Arg367 and Asp478 are conserved in both domains (Fig. 1F).

Homologous YARS1 c.1099C>T, p.(Arg367Trp) variant causes a distinct multisystem disease

We characterized the clinical features of the ten newly identified patients (families 1–4, 6) and two previously published patients (family 5) with homozygous p.(Arg367Trp) variants, all presenting with moderate ID and multisystem disease (Table 1, Fig. 1A–G) [15]. Family 1 originates from Turkey and family 5 originates from Iran close to the border to Turkey. Families 2, 3, and 4 stem from three different regions in Saudi Arabia. Family 6 originates from Puerto Rico.

The individuals were born at term. Body measurements at birth, including weight, length, and head circumference, were at the lower end of the range. The weight at birth ranged between −0.8 and −2.8 standard deviations (SD) (5/5) (medium − 1.8 SD).

All individuals, of whom data were available, had acquired microcephaly (12/12, 100%), a postnatal failure to thrive or growth delay (11/12, 92%) and developmental delay or intellectual disability (12/12, 100%). Most individuals learned to walk independently (9/12, 75%, average age 3.3 years, SD 0.7) and all acquired the ability to communicate using single words (11/12, 92%, average age 3.4 years, SD 1.3). At the age of last evaluation, almost half of the individuals were able to follow simple demands (5/12, 42%), but only one individual spoke simple sentences of three or more words (1/12, 8%, 8.5 years). Neurological assessment revealed muscular hypotonia (9/12, 75%) including the face (6/10, 60%), ataxia (7/10, 70%), and a poor coordination (5/8, 63%). None of the patients had a history of epilepsy. Seven patients were reported to have abnormal liver findings including hepatomegaly (7/7, 100%), hypercholesterinemic liver texture on ultrasonography (5/7, 71%), or an episode of elevated liver enzymes (1/11, 9%) suggestive of stable liver disease with steatosis. Serum albumin was in the lower normal reference range (mean ± SD, 3.4 ± 0.5 g/L). Until the last investigation (oldest age 15 years), only one patient had a history of temporary ascites and no patient showed clinical signs of liver failure. All individuals who had a blood analysis done displayed a chronic microcytic anemia (8/8, 100%, mean ± SD, hemoglobin 10.9 ± 0.9 g/dl, MCV 63.9 ± 2.2 fl, MCH 19.6 ± 1.4 pg). Almost half of patients had laboratory results suggestive of hypothyroidism (4/9, 44%). Sporadic findings and features included mild hearing impairment (1/12, 8%), gastroesophageal reflux and vomiting (2/12, 17%), abnormal findings on chest X-ray (2/11), dyspnea
(1/12, 8%), recurrent obstructive pulmonary disease (1/12, 8%), and recurrent infections (1/12, 8%). MRI imaging of the head revealed a reduced brain volume (7/9, 78%), a thin corpus callosum (6/9, 67%), and a delay in myelination (6/9, 67%) (Fig. 2). Patients displayed facial dysmorphic features including a flat philtrum (6/7, Fig. 2 B–G), a open mouth appearance (6/7, Fig. 2 B, D, F, G), deep set eyes (5/7, Fig. 2 B, C, D, G), hanging columella (5/7, Fig. 2 B, C, D, F, G), a prominent nose tip with relative small nares (3/7, Fig. 2 B, C, D), low set (1/7, Fig. 2 F), and large ears (4/7 Fig. B, C, D), sparse hair (4/7, Fig. 2 E–G), together reminding of a progeroid-like appearance (6/6, Fig. 2 B–G).

In summary, the homozygous missense variant p. (Arg367Trp) causes a clinically consistent, multisystem disease with mildly delayed motor and severely impaired speech development, microcephaly, failure to thrive, short stature, muscular hypotonia, ataxia, brain atrophy, microcytic anemia, hepatomegaly, hypothyroidism, and facial features including a deep set eyes, a flat philtrum, and open mouth appearance. Clinical heterogeneity is only observed for hypothyroidism (approximately 50% of patients affected) and some sporadic findings such as hearing loss or gastroesophageal reflux.

**YARS1** is one of the established disease genes of CMT. Patients and their parents had no peripheral palsy, impairment of peripheral sensation, autonomic dysfunction, or neuropathic pain. In conclusion, no clinical signs of peripheral neuropathy were present. In four patients, peripheral nerve conduction studies were performed which showed unremarkable amplitudes of sensory action potentials and normal nerve conduction velocities. Detailed case reports and medical histories are reported in the supplementary material.

### Review of individuals from the literature: allelic and clinical heterogeneity associated with biallelic variations in **YARS1**

In the recent literature, five homozygous or compound heterozygous disease-causing variants in **YARS1** other than p. (Arg367Trp) have been described (Table 2).

In 2016, two siblings with compound heterozygous likely pathogenic variants c.638C>T, p. (Pro213Leu) and c.1573G>A, p. (Gly525Arg) in **YARS1** were reported. They were affected by mild developmental delay (1/2) or normal development (1/2), failure to thrive in the first year of life, short stature, microcephaly (1/2), stable liver disease with...
Table 1 Clinical features of 12 individuals homozygous for NM_003680.3(YARS1):c.1099C>T, p.(Arg367Trp). Features with a frequency reported ≥ 2 times were reported in this table.

| Features | Family 1 | Family 2 | Family 3 | Family 4 | Family 5 | Family 6 |
|----------|----------|----------|----------|----------|----------|----------|
|          | A:II-1   | B:II-2   | C:II-2   | D:II-3   | E:II-5   |          |
| Sex      | M        | M        | F        | F        | F        | F        |
| Ethnicity| Turkish  | Arabian  | Arabian  | Arabian  | Iranian  | Puerto-
|          |          |          |          |          | Rican    | Rican    |
| Age at last exam (years) | 15 | 9 | 5 | 14 | 11 | 7 | 6 | 3 | 4 | 15 | 13 | 4 |
| Body measurements | | | | | | |
| Microcephaly | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 12/12 (100%) |
| Birth (weeks) | 39 | 40 | 39 | n/r | n/r | 40 | 40 | 40 | 39 | 38 | 38 | 40 |
| - weight at birth (g)/(SD) | 2600/−2.0 | 2910/−1.7 | 3000/−0.8 | n/r | n/r | 2900/−1.8 | n/r | n/r | 3285/−0.77 |
| -Length at birth (cm)/(SD) | 49/−1.6 | 48/−2.0 | n/r | n/r | n/r | n/r | n/r | n/r | 49/−1.3 |
| -OFV at birth (cm)/(SD) | 34/−1.0 | 33/−2.0 | n/r | n/r | n/r | n/r | n/r | n/r | 33/−2.0 |
| Failure to thrive | + 6 3/12 | + 7 6/12 | + 5 7/12 | + n/r | + 3/12 | + | + | + 4 5/12 | + 14 | + 13 | + 3 6/12 | 11 12 (92%) |
| Age of measurement (y) | | | | | | | | | | | | |
| -Weight (kg)/(SD) | 15/−2.9 | 17.3/−3.1 | 12.6/−2.7 | n/r | n/r | 1.7/−5.4 | <3rd | <3rd | 12.2/−3.2 | n/r | n/r | 12.3/−1.8 |
| -Length (cm)/(SD) | 108/−3.3 | 112/−2.7 | 102/−3.6 | n/r | n/r | <3rd | <3rd | <3rd | 94/−3.0 | 122/−5.1 | 120/−4.6 | 94/−1.4 |
| -OFV (cm)/(SD) | 48/−3.6 | 47/−4.4 | 45/−5.5 | n/r | n/r | <3rd | <3rd | <3rd | 45/−5.1 | 44/−6.7 | 47/−4.8 | 47/−3.1 |
| Cogntive development and acquired skills | | | | | | | | | | | | |
| Intellectual disability (IQ) | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | (30) | (30) | + | 12/12 (100%) |
| Developmental delay | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | 12/12 (100%) |
| Ability to sit alone—age | 2 y | n/r | n/r | n/r | n/r | 2.5 y | 2 y | 2 y | 1 y | 1 y 8 m | 1 y 8 m | 1 y | 88 (100%) |
| Ability to walk—age | 3 y | 3.5 y | 3 y | 3 y | 2 y | No (7) | 4 y | No (3) | No (4) | 4 y | 4 y | 2.5 y | 9/12 (72%) |
| Speech—single words | 3.5 y | 3 y | 4 y | 4 y | 3 y | 6 y | 5 y | 2–3 y | 2 y | 2 y | 2 y | No | 11/12 (92%) |
| Speech—simple sentences | 8.5 y | No | No | No | No | No | No | No | No | No | No | No | 1/12 (8%) |
| Follows simple demands | + | + | + | + | + | No | No | No | No | No | No | No | 5/12 (42%) |
| Neurological findings | | | | | | | | | | | | |
| Muscular hypotonia | + | + | - | - | - | - | + | + | + | + | + | + | + | + | + | 9/12 (75%) |
| Ataxia | + | + | + | + | + | + | + | + | + | + | + | + | + | 7/10 (70%) |
| Poor coordination | + | + | n/r | n/r | n/r | - | - | - | n/r | + | + | n/r | 5/8 (63%) |
| Facial hypotonia | + | + | - | - | - | - | + | n/r | n/r | - | + | + | + | 6/10 (60%) |
| Seizures | - | - | - | - | - | - | - | - | - | - | - | 0/12 (0%) |
| Liver | | | | | | | | | | | | |
| Hepatomegaly | n/r | + | n/r | n/r | n/r | n/r | + | + | + | + (mild) | + | + | n/r | 7/7 (100%) |
| Hyperechogenic liver texture | n/r | + | n/r | n/r | n/r | n/r | + | + | + | + (mild) | - | - | n/r | 5/7 (71%) |
| Elevated liver enzymes | - | - | - | n/r | n/r | - | - | - | One episode | n/r | n/r | - | 1/8 (13%) |
| History of Ascites | - | - | - | - | - | - | - | + | - | - | - | - | 1/12 (9%) |
| Liver failure | - | - | - | - | - | - | - | - | - | - | - | - | 0/12 (0%) |
| Abnormal laboratory findings | | | | | | | | | | | | |
| Chronic anemia | + | + | + | n/r | n/r | + | + | + | + | n/r | n/r | + | 8/8 (100%) |
| Table 1 (continued) |  |
|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| NM_003680.3(YARS1):c.1099C>T, p.(Arg367Trp) |  |
| Hypothyroidism | + | - | - | - | - | + | + | + | - | n/r | n/r | n/r | 49 (44%) |  |
| Growth hormone deficiency | + | - | n/r | n/r | n/r | n/r | n/r | n/r | n/r | n/r | n/r | 1/2 (50%) |  |
| **Brain imaging (MRI)** |  |
| Age | 12 | 2/12 | 1 6/12 | 1.5 y | 2 y | n/r | 1 y | 3 y | 2 y | 2 y | 2 y | n/r | n/r | n/r | 9/11 (81%) |  |
| Thin corpus callosum | + | + | - | - | - | + | + | + | + | n/r | n/r | n/r | 69 (67%) |  |
| Reduced brain volume | + | + | - | - | - | + | + | + | + | n/r | n/r | n/r | 79 (78%) |  |
| Delay in myelination | + | + | - | - | - | + | + | + | + | n/r | n/r | n/r | 69 (67%) |  |
| Other findings | - | + (#) | - | - | - | - | + ($) | - | - | n/r | n/r | - | 29 (11%) |  |
| **Nerve conduction—sensory potentials** |  |
| Decreased velocity | - | - | n/r | n/r | n/r | n/r | n/r | n/r | n/r | - | n/r | 04 (0%) |  |
| Decreased amplitude | - | - | n/r | n/r | n/r | n/r | n/r | n/r | n/r | - | n/r | 04 (0%) |  |
| **Other findings** |  |
| Visual impairment | - | - | - | - | - | - | - | - | - | n/r | n/r | - | 0/11 (0%) |  |
| Retinal degeneration | - | - | - | n/r | n/r | n/r | - | - | - | n/r | n/r | - | 0/6 (0%) |  |
| Hearing loss | - | - | - | - | - | + | - | - | n/r | - | + | - | 2/12 (17%) |  |
| Vomiting | - | - | - | - | - | + | - | - | - | - | - | + | 2/11 (18%) |  |
| Gastroesophageal reflux | - | - | - | - | - | + | - | - | - | - | - | + | 2/11 (18%) |  |
| Dyspnea | - | - | - | - | - | + | n/r | n/r | - | - | - | - | 1/10 (10%) |  |
| Chest X-ray | n/r | n/r | Normal | +(#) | n/r | n/r | +(§) | n/r | n/r | n/r | n/r | n/r | n/r | n/r | n/r |  |
| Recurrent bronchitis | + | - | - | - | - | - | - | - | - | - | - | - | 1/12 (8%) |  |
| Pancreatitis | - | - | - | - | - | - | - | - | - | - | - | - | 1/12 (8%) |  |
| Cardiovascular/urinary abnormalities | - | + (&) | - | - | - | + (+) | - | - | - | - | - | - | 2/12 (17%) |  |
| Recurrent infections | - | - | - | - | - | + ($) | - | - | - | - | - | - | 1/12 (8%) |  |
| **Mortality—age (years)** |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15 |  |

* Arachnoid cyst 6×3×3 cm
* periventricular leucomalacia
* hydro-nephrosis of right kidney
* PDA, muscular ventricular septal defect
** hypoplastic right lung
& perihilar bronchial wall thickening
MRI, magnet resonance imaging
OFC, occipitofrontal circumference
n/r, not reported
SD, standard deviation
steatosis (without inflammation), hypercholesterinemia, areflexic muscular hypotonia (1/2), cystic lung disease, and non-progressive mild brain atrophy and thinning of corpus callosum with cystic changes in periventricular white matter [18]. The nerve conduction was not affected and both parents had no evidence of neuropathy or neurological disease.

In 2017, the homozygous variant c.806 T>C, p.(Phe269Ser) in YARS1 in one individual was associated with poor weight gain (necessitating tube feeding), severe visual impairment caused by progressive-rod-cone degeneration (fundus pigmentation), profound hearing impairment, poor balance and muscular hypotonia during first years of life, stable liver disease with steatosis (later minor fibrotic changes), primary amenorrhea, but normal psychomotor development [14]. MRI images revealed a thin corpus callosum. Laboratory analyses showed high level of blood platelets related to hyperactive bone marrow.

In 2019, seven related individuals with a homozygous c.499C>A, p.(Pro167Thr) pathogenic variant within the catalytic N-terminal domain of YARS1 were reported to be affected by a more severe multisystem disorder than previously reported [17]. All patients had developmental delay, microcephaly, bilateral sensorineural hearing loss, and poor growth. Some patients had abnormal ophthalmological findings including pigmented degeneration and visual impairment. They were affected by exocrine pancreatic insufficiency and chronic, progressive liver disease with steatosis at the early stages, and inflammatory cirrhosis at the later stages. MRI images of the head revealed restricted diffusion among the white matter and abnormal T2-weighted hyperintensity with dysmyelination. Autopsy of one of the deceased patients showed evidence of chronic neuronal loss with vacuoles. Laboratory analyses showed chronic anemia, hypalbuminemia, and intermittent proteinuria. Four patients died during the first 2 years of life due to progressive liver failure.

In 2019, in a large cohort of patients with microcephaly, the homozygous variant c.789C>A, p.(Pro213Leu) in YARS1 was associated with microcephaly, developmental delay and primordial dwarfism in one girl [16].

In summary, recessively inherited variants in YARS1 cause some overlapping clinical features including small stature and motor problems (all published variants). There are also decisive differences between clinical features associated with the different variants.

The neurological impairment of p.Pro167Thr, p.(Arg367Trp), and p.(Phe263Leu) is much more severe when compared to p.(Phe269Ser) or the compound heterozygous variants p.(Pro213Leu) and p.(Gly525Arg). For almost all variants, some liver involvement has been reported, ranging from mild steatosis (p.(Pro213Leu)/p.(Gly525Arg); p.(Phe269Ser); p.(Arg367Trp)) to cirrhosis and hepatic failure (p.Pro167Thr). Abnormal blood cells (anemia or low platelets) are reported in association with p.(Phe269Ser), p.Pro167Thr, and p.(Arg367Trp).

Discussion

Since the availability and broad use of exome sequencing, the success rate in solving the genetic cause of ID and multisystem diseases has significantly increased. Most of the new disease genes have been identified as private disease-causing variants in single families within larger cohorts [15, 16, 27]. For many disease genes, reliable clinical data on the features and course of the associated disorders are sparse. For appropriate patient counseling and guidance, the delineation of typical clinical signs is needed.

Aminoacyl-tRNA synthetases link specific amino acids with their transfer RNAs and play a key role in protein translation. Beyond their canonical role, many ARS1 acquired secondary functions by the incorporation of additional domains during evolution of more complex eukaryotes and play key regulatory roles e.g. in immunomodulation and inflammation [28–31].

TyrRS couples the amino acid tyrosine to its specific tRNA. In this study, we identified and characterized 10 newly diagnosed and two previously reported individuals carrying the homozygous nonsense variant NM_003680.3:c.1099C>T, p.(Arg367Trp) in YARS1 and summarized all previously published patients from the literature, carrying alternative, biallelic variants in YARS. We identified a specific multisystem disease affecting not only the central nervous system, but also the liver, the hematopoietic system (anemia), and the endocrine system (hypothyroidism). The specification of the common, clinical features allows to establish the recommendation of monitoring affected individuals with regards to psychomotor, liver,
Fig. 2 a Pedigrees of affected individuals with homozygous p.(Arg367Trp) in YARS1. Individuals J and K had been reported within a large cohort of consanguineous families with ID [15]. Individual L additionally has two unaffected half-siblings (not depicted).

b-h Facial features of individuals (A+B, F+G+H, I, and L). b Individual A (family 1:II-1) at age of 11 and 15 years, c Individual B (family 1:II-2) at age of 7 and 9 years, d Individual I (family 4:II-1) at age of 7 years, e Individual F (Family 3:II-3) at age of 3 years, f Individual H (family 3:II-5), g Individual G (family 3:II-4) at age of 5 years, h Individual L (Family 6:II-41) at age of 3.5 years. Facial dysmorphic features including deep set eyes (b–h), a long nose (b–d), a flat nasal bridge (b–d), full cheeks (E–G), long columella (c–d, f–g), flat philtrum (b–h), open mouth appearance (b, d–h), low set (1), and large ears (b–d, h), together resembling progeroid-like appearance (b–h).

i Axial sequences (head MRI) of individuals I, G, and F showing wide lateral ventricles as a sign of diffuse cerebral volume due to periventricular white matter loss.

j Sagittal sequences (head MRI) of individuals I (2y), G (2y), and F (2y) (from left to right) showing thinning of corpus callosum.
Table 2. Summary of all patients with biallelic variants in YARS1 other than p.(Arg367Trp) from the literature. *In silico* analysis with VIPUR algorithm predicts that all biallelic variants associated with recessive multisystemic disease significantly impact the protein structure and stability (score > 0.5) of the respective TyrRS protein domain

|                  | Nowaczyk et al. 2016 | Tracewska-Siemiatkowska et al., 2017 | Williams et al., 2019 | Alkuraya et al., 2019 | This study |
|------------------|-----------------------|---------------------------------------|------------------------|------------------------|------------|
| Gender           | 2 patients            | 1 patient                             | 7 patients             | 1 patient              | 12 patients |
| Origin           | Polish                | Swedish                               | Amish (USA)            | Saudi Arabian          | Turkish/Iranian/Saudi Arabian/Puerto-Rican |
| Variant          | p.(Pro213Leu) p.(Gly525Arg) * | p.(Phe263Leu) | p.Pro167Thr | p.(Phe263Leu) | p.(Arg367Trp) |
| Domain           | N-terminal catalytic domain and C-terminal EMAP-II-like domain | tRNA anti-codon-binding domain | N-terminal catalytic domain | tRNA anti-codon-binding domain | C-terminal EMAP-II-like domain |
| VIPUR Score      | 0.84                  | 0.86                                  | 0.73                   | 0.67                   | 0.90       |
| Pregnancy/birth  | Normal                | Normal                                | 3/7: premature         | Primal dwarfism        | Body measurements at birth in lower range |
|                  | No complications      | No complications                      | 5/7: placental anomalies | 4/7: growth restriction |
| Short stature    | +                     | 1/2                                   | +                      | +                      | +          | 9/9       |
| Failure to thrive| +                     | 2/2                                   | +                      | +                      | +          | 10/12     |
| Microcephaly     | +                     | 1/2                                   | -                      | +                      | +          | 12/12     |
| Developmental delay | ± 1/2 ^               | ±                                      | +                      | +                      | +          | 12/12     |
| Muscular hypotonia | + 2/2                 | +                                     | +                      | n/r                    | +          | 9/12      |
| Poor coordination| -                     | 0/2                                   | +                      | 7/7                    | n/r        | 5/8       |
| Hearing loss     | -                     | 0/2                                   | +                      | 7/7                    | n/r        | 2/11      |

*Present in > 50%; ± present in 5–50%; "absent
compound heterozygous
^Mild

^a at age of 7 months after anoxic brain injury

^C steatosis

^b cirrhosis

^c cystic changes

^d dysmyelination, diffusion restriction, T2 hyperintensity

^e during first 2 years; n/r, not reported
hematological, and hormonal symptoms. In addition, the identification of total 12 patients with a matching and common clinical phenotype confirms the classification of the variant p.(Arg367Trp) to be unequivocally pathogenic.

We originally intended to include patients with multisystem disorders caused by biallelic variants in YARS1, regardless of the specific variants. Interestingly, our efforts that included GeneMatcher and international collaborations, only identified additional patients that were homozygous for the p.(Arg367Trp) variant. We therefore compared the allele frequency of the published variants to the frequency of p.(Arg367Trp) in population databases. p.(Arg367Trp) and the other variants from the literature have not been identified in any of the control individuals from theIranome or GME Variome projects [32, 33]. In gnomAD v2.1.1, the higher allele frequency of p.(Arg367Trp) (11 among a total of more than 141,000 individuals) compared to variants from the previous publication (0–2 alleles among more than 141,000 individuals) in the general population probably accounts for the higher prevalence of homozygous p.(Arg367Trp) and explains why we identified an unexpected and disproportionate high number of patients with this specific variant [26]. Despite predominant reports of heterozygotes in the Latino population, we only recruited one patient originating from Latin America (Patient L, Puerto Rico). A possible reason might be the relatively rare application exome sequencing in Latin America, or the predominant random-mating scheme in contrast to the prevalent consanguineous mating which is common in Middle East and South Asia. Of note, many variants causing autosomal recessive disorders in communities with high consanguinity rates occur as private disease-causing variants in single families. This also seems to be the case for the previously published individuals with variants that are absent from established control databases. In contrast, the variant p.(Arg367Trp) is reported with a much higher frequency and, therefore, might be of high and notable clinical relevance. Haplotype analysis of our patients revealed diverging haplotypes surrounding the YARS1 gene region suggesting that p.(Arg367Trp) does not essentially trace back to a single founder.

As a native protein TyrRS comprises three functional domains: the catalytic domain, the anticodon-binding domain, and the C-terminal domain. TyrRS is only catalytically active as a homodimer [34–36]. While the full-length, dimeric TyrRS (528 AA) has no known additional cytokine activity, proteolytic cleavage and dissociating of monomeric TyrRS into the N-terminal TyrRSMini (composed of the catalytic and anticodon domain) and a C-terminal EMAP-II-like domain (164 AA) activates the secondary functions of these domains [1, 2].

Many genes involved in protein synthesis have been associated with neurodevelopmental disorders [37, 38]. In view of the core function of TyrRS in aminoacylation, it is tempting to expect that a limited protein synthesis which might not meet translational demand causes YARS1-associated disorders. Based on our findings, the hypothesis conferring that a dysbalanced protein homeostasis is the sufficient explanation of YARS1-associated disorders must be questioned for several reasons. First, the hypothesis of impaired protein synthesis lacks to explain the considerable clinical variability of autosomal recessive diseases associated with YARS1 and also other ARS1-deficiencies. If a reduced or less specific enzyme activity was the common cause of disease, we would expect a more homogeneous clinical presentation of all biallelic YARS1 and other ARS1 pathogenic variants. Second, pathogenic variations causing recessive ARS1 deficiencies generally reside in catalytic or anticodon binding domains of ARS1 genes. However, in silico analysis show that p.(Arg367Trp) lie outside these catalytically important domains, but that they are located in the C-terminal domain that accounts for non-canonical, immunomodulatory functions [18].

It was shown that the cleaved N-terminal TyrRSMini retains the aminoacylation activity of native TyrRS, and thus, the C-terminal EMAP-II-like domain was shown to be dispensable for aminoacylation [1, 39]. Therefore, p.(Arg367Trp) that resides in the C-terminal domain probably does not affect the aminoacylation activity of TyrRS. In silico analyses show that Arg367 is critical for a tight electrostatic interaction with the oppositely charged Asp478 and that p.(Arg367Trp) reduces the domain stability of the C-terminal EMAP-II-like domain which is in close vicinity of the critical hexapeptide stretch of this domain (residues 371–377). As a consequence, the destabilization of the protein structure could disrupt the EMAP-II-like cytokine activity. EMAP-II is also known as the aminoacyl-tRNA multiple synthetase complex (MSC) Interacting Multifunctional Protein 1 (AIMP1). The EMAP-II-like domain of YARS1 shares 51% identity (78% similarity) including Arg367 (Fig. 1F). It plays a role in the assembly of the multiple synthetase-complex (MSC), and once it is secreted from apoptotic cells confers multiple effects on angiogenesis, wound healing, glucose metabolism, and neuronal development [40]. Of note, Arg367 and Asp478 are not only highly conserved in the C-terminal domain of TyrRS, but also its corresponding residues in the homologue EMAP-II underpinning their importance for the protein function (Fig. 1F). Homozygous pathogenic variants in AIMIP1 have been reported to cause moderate to severe intellectual disability suggesting that imbalances in EMAP-II-like functions are sufficient to cause developmental disorders [41, 42].

Apart from its procytokine activity, the C-terminal domain functions to sterically block the critical chemotactic ELR motif in the N-terminal domain by mutual shielding [43]. By this mechanism, the C-terminal domain is thought to suppress the cytokine activity of TyrRS in the state of a
native full-length protein [43]. Thus, destabilization of the C-terminal domain could impede the steric block of the ELR motif and thus induce a proinflammatory phenotype. The finding of hyperechogenic liver cirrhosis in our patients and patients from the literature, potentially supports the idea that an imbalanced immune response and excessive inflammation may play a role in the underlying disease pathophysiology. The finding of chronic, microcytic anemia in relation to normal ferritin and low reticulocytes could also be explained by a chronic inflammatory condition.

The phenotypic spectrum of the disorder associated with p.(Arg367Trp) overlaps, but also differs to a certain extent from other reported pathogenic variants in YARS1 from the literature. In silico analysis of the protein structure predict a significant impact of all previously reported recessive variants on the stability of the respective TyrRS protein domain. Compared to the homozygous variant p.(Pro167Thr) that causes a severe multisystem disorder including the liver, the pancreas and the kidneys and a high infant mortality, p.(Arg367Trp) is associated with a milder clinical presentation [17]. In contrast, the compound heterozygous variants p.(Pro213Leu)/p.(Gly525Arg) and p.(Phe269Ser) were described to compromise the auditory perception, eyes, reproductive organs, and liver, while not causing ID [14]. These observations suggest that YARS1 displays considerable allelic heterogeneity concerning the disease severity and pattern. p.(Pro167Thr) at the severe end of the spectrum and p.(Pro213Leu) at the mild end of the spectrum both reside in the N-terminal catalytic domain of YARS1, while p.(Arg367Trp) with a disease severity in between these both domains is located in the C-terminal domain. Given the limited number of variants described so far and the phenotypic heterogeneity associated with the different domains, it is difficult to draw a clear link between the affected domain and the disease severity and organs involved.

The hypothesis that autosomal recessive disorders associated with YARS1 are caused by dysregulated secondary functions rather than only by impaired protein synthesis is further supported by location of the variations reported in patients from the literature outside the TyrRS catalytic domain (e.g., p.(Gly525Arg) in the C-terminal domain).

Until recently, all 19 ARS1 have been associated with autosomal recessive diseases [8]. While recessively inherited ARS1 disorders share some common clinical signs, e.g., involvement of the CNS and microcephaly (in all but HARS1), there is a striking heterogeneity of the clinical manifestation which does not follow a reproducible pattern. Liver involvement has been reported for IARS, Lars, and MARS while for example skin anomalies have only been described for QARS or anatomical heart anomalies have only been described for MARS [38, 44–49]. LARS1- and MARS1-associated disorders are associated with neurological impairment, MRI abnormalities, liver disease, anemia, and endocrine abnormalities and show the greatest clinical overlap with the YARS1 p.(Arg367Trp)-associated phenotype delineated here.

Another example of ARS1-associated disorders, in which an impaired protein synthesis as the causative disease mechanism can be questioned is VARS1 causing developmental delay with microcephaly [38]. Interestingly, in in vitro assays, the authors found a 50% residual aminoacylation activity. Because reductions in enzyme activity of approximately 50% are often well tolerated, it can be speculated that reduced aminoacylation is not the underlying disease mechanism, but that dysregulated secondary functions (for example, dysregulation of VEGF) might be involved. In many ARS1 genes, over 200 “catalytic nulls” natural splice variants have been annotated which primarily ablate or disrupt the catalytic domain but retain the noncatalytic section. This observation underpins the diverse, functions of nonenzymatic domains of ARS1 genes [50].

CMT is another disease reflecting the significance of secondary protein functions of YARS1. Since the discovery of pathogenic variants in YARS1 causing CMT type C more than 15 years ago, the exact disease mechanism has not been understood, yet. All five CMT-causing mutations in YARS1 reside in the N-terminal catalytic domain (Fig. 1A). Because aminoacylation activity is not a shared property of pathogenic variations, it is unlikely that haploinsufficiency affecting the aminoacylation enzyme activity is the underlying mechanism [7, 51]. Currently, gain-of-function pathogenic variants in non-catalytic domains or transcriptional dysregulation are discussed to be the potential underlying disease mechanism [52]. Of note, none of the patients or parents reported here is affected by CMT neuropathy. This is in line with the absence of neuropathy in patients with recessive disorders caused by other ARS1 genes which have been implicated with CMT [8].

One limitation in the interpretation of the impact of YARS1 variants on protein function is that to date no structural model of the full-length protein is available and that separate structures of mini-TyrRS and C-domains are the basis for functional predictions. Another limitation is that our assumptions are based on clinical findings, in silico analyses, and on recent findings from functional in vitro studies. Protein dimerization assays and yeast growth complementation assays have been performed for YARS1 p.(Pro167Thr) showing impaired dimerization and limited yeast growth [17]. Functional studies for p.(Arg367Trp) have not been performed. As the C-terminal domain was shown to be dispensable for aminoacylation, it can be supposed that p.(Arg367Trp) residing in the C-terminal domain does not affect the enzymatic function of TyrRS; however, indirect effects on enzymatic function cannot be ruled out [1, 39]. Experimental studies will be required.
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00109-021-02124-9.

Acknowledgements We thank the patients and their families for taking part in this study. This work was partly done within the Zentrum für Seltene Erkrankungen of the University Hospital Düsseldorf (ZSED). One of the authors of this publication (D.W.) is member of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516].

Author contributions Conceptualization: L.A., H.St., A.R., F.S.A., D.W.; Methodology: L.A., H.S.A., D.W.; Formal analysis and investigation: L.A., H.St., H.S., J.-J.L.; Data acquisition: L.A., M.K., H., K.K., H.S.A., B.S.A., B.M.T., C.K., S.E.; H.N., F.S.A., A.R., S.E., D.W., S.E., E.W., J.K. Funding acquisition: A.R., H.N., F.S.A., D.W.; Visualisation: L.A., H.St., H.S. Writing – original draft: L.A.; H.St., Writing – review & editing: H.St., H.S., H.-J.L., F.S.A., D.W.

Funding Open Access funding enabled and organized by Projekt DEAL. This work was in part supported by the German Ministry of Research and Education (01GS01617 (DW)) and BMBF German Mental Retardation Network (01GM1520A (AR)), German Mental Retardation Network as part of the National Genome Research Network. SE was supported by an MRC strategic award to establish an International Research Network (01GM1520A (DW)).

Data availability Additional clinical data and materials will be individually available upon request.

Declarations

Ethics approval The study was approved by the institutional ethical review boards (King Faisal Specialist Hospital and Research Center; Ref. No # 2121053 and 2080006; University Hospital Erlangen Ref. No. 253_15B).

Consent to participate Informed consent was obtained from legal guardians.

Consent for publication Written informed consent for publishing of clinical, genetic data and photographs was obtained from the legal guardians.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Wakasugi K, Schimmel P (1999) Two distinct cytokines released from a human aminoadyl-tRNA synthetase. Sci 284(5411):147–151. https://doi.org/10.1126/science.284.5411.147
2. Wakasugi K, Slike BM, Hood J, Ewald KL, Cheng DA, Schimmel P (2002) Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase. J Biol Chem 277(23):20124–20126. https://doi.org/10.1074/jbc.C200126200
3. Kanaji T, Vo MN, Kanaji S, Zarpeilin A, Shapiro R, Morodomi Y, Yuzurui A, Eto K, Belani R, Do MH et al (2018) Tyrosyl-tRNA synthetase stimulates thrombopoietin-independent hematopoiesis accelerating recovery from thrombocytopenia. Proc Natl Acad Sci USA 115(35):E8228–E8235. https://doi.org/10.1073/pnas.1807000115
4. Kao J, Ryan J, Brett G, Chen J, Shen H, Fan YG, Godman G, Familietti PC, Wang F, Pan YC et al (1992) Endothelial monocyte-activating polypeptide II: A novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem 267(28):20239–20247
5. Kao J, Fan YG, Hahnel I, Brett J, Greenberg S, Clauss M, Kayton M, Houck K, Kiesiel W, Seljeld R et al (1994) A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions defines an apparently novel cellular interaction site and induces an acute inflammatory response. J Biol Chem 269(13):9774–9782
6. Wakasugi K, Schimmel P (1999) Highly differentiated motifs responsible for two cytokine activities of a split human tRNA synthetase. J Biol Chem 274(31):23155–23159. https://doi.org/10.1074/jbc.C200126200
7. Jordanova A, Irobi J, Thors FP, Van Dijck P, Meerschaert K, Dewil M, Dierick I, Jacobs A, De Vriendt E, Guggeuechtcheva V et al (2006) Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat Genet 38(2):197–202. https://doi.org/10.1038/ng1727
8. Fuchs SA, Schne IF, Kok G, Janssen JM, Nikkels PGJ, van Gassen KLI, Terheggen-Lagroy SWJ, van der Crabben SN, Hoeks SE, Niers LEM et al (2019) Aminoadyl-tRNA synthetase deficiencies in search of common themes. Genet Med 21(2):319–330. https://doi.org/10.1002/gjme.731
9. McLaughlin HM, Sakaguchi R, Liu C, Igarashi T, Pehlivan D, Chu K, Iyer R, Cruz P, Cherukuri PF, Hansen NF et al (2010) Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy. Am J Hum Genet 87(4):560–566. https://doi.org/10.1016/j.ajhg.2010.09.008
10. Antonellis A, Ellsworth RE, Sambaghlin N, Puls I, Abel A, Lee-Lin SQ, Jordanova A, Kremensky I, Christodoulou K, Middleton LT et al (2003) Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet 72(5):1293–1299. https://doi.org/10.1086/375039
11. Latour P, Thauvin-Robinet C, Baudet-Mery C, Soichot P, Cusin V, Favier L, Locatelli MC, Mayencon M, Sarcey A, Broussole E et al (2010) A major determinant for binding and aminocyclation of tRNA(Aa) in cytoplasmic Alanylation synthetase is mutated in dominant axonal Charcot-Marie-Tooth disease. Am J Hum Genet 86(1):77–82. https://doi.org/10.1016/j.ajhg.2009.12.005

12. Gonzalez M, McLaughlin H, Houlden H, Guo M, Yo-Tsen L, Hadjivassiliou M, Speziani F, Yang XL, Antonellis A, Reilly MM et al (2013) Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2. J Neurol Neurosurg Psychiatry 84(11):1247–1249. https://doi.org/10.1136/jnnp-2013-305049

13. Sutka Brozovka D, Deconinck T, Griffin LB, Herbert A, Haberlova I, Mazanec R, Lassathova P, Roth C, Phumlathanakul T, Rautenstrauss B et al (2015) Loss of function mutations in HARS cause a spectrum of inherited peripheral neuropathies. Brain 138(8 Pt 2):2161–2172. https://doi.org/10.1093/brain/awv1158

14. Tracewski-Siemiatkowska A, Haer-Wigman L, Bosch DGM, Nickerson D, Bambash MJ, van de Vorst M, Rendtorff ND, Moller C, Kjellstrom U, Arendsson S et al (2017) An Expanded Multi-Organ Disease Phenotype Associated with Mutations in YARS. Genes (Basel) 8(12):381. https://doi.org/10.3390/genes8120381

15. Hu H, Kahrizi K, Musante L, Fattahi M, Herwig R, Hosseini M, Oppitz C, Amini SH, Suckow V, Larti F et al (2019) Genetics of intellectual disability in consanguineous families. Mol Psychiatry 24(7):1027–1039. https://doi.org/10.1038/s41380-017-0012-2

16. Shaheen R, Maddirevula S, Ewida N, Alsahli S, Abdel-Salam GMH, Zaki MS, Tiao G, Cummings BB, Alfoldi J, Mazumder B, Seshadri V, Gerber CA, Chavatte L, Kinter M, Ting SM, Dignam JD, Kim S, Driscoll DM, Fox PL (2004) Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific silencing of translation. Cell 119(2):195–208. https://doi.org/10.1016/j.cell.2004.09.030

17. Williams KB, Brigatti KW, Puffenberger EG, Gonzaga-Jauregui C, Griffin LB, Martinez ED, Wengler OK, Yoder MA, Kandula MM et al (2013) Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2. J Neurol Neurosurg Psychiatry 84(11):1247–1249. https://doi.org/10.1136/jnnp-2013-305049

18. Nowaczyk MJ, Huang L, Tarnopolsky M, Cheresh D, Schimmel P, Friedlander M (2017) VARS, a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424. https://doi.org/10.1038/gim.2015.30

19. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP et al (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581(7809):434–443. https://doi.org/10.1038/s41586-020-2308-7

20. Reuter MS, Tawamie H, Buchert R, Hosny Gebril O, Froukh T, Chiel C, Uebe S, Ekici AB, Krumbiegel M, Zweier C et al (2017) Diagnostic Yield and novel candidate genes by exome sequencing in 152 consanguineous families with neurodevelopmental disorders. JAMA Psychiat 74(3):293–299. https://doi.org/10.1001/jamapsychiatry.2016.3798

21. Sampath P, Mazumder B, Seshadri V, Gerber CA, Chavatte L, Kinter M, Ting SM, Dignam JD, Kim S, Driscoll DM, Fox PL (2004) Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific silencing of translation. Cell 119(2):195–208. https://doi.org/10.1016/j.cell.2004.09.030

22. Mukhopadhyay R, Jia J, Arif A, Ray PS, Fox PL (2009) The GAIT system: a gatekeeper of inflammatory gene expression. Trends Biochem Sci 34(7):324–331. https://doi.org/10.1016/j.tibio.2009.03.004

23. Otani A, Slikke BM, Dorrell MI, Hood J, Kinder K, Ewalt KL, Chereshe D, Schimmel P, Friedlander M (2002) A fragment of human TrpRS as a potent antagonist of ocular angiogenesis. Proc Natl Acad Sci USA 99(1):178–183. https://doi.org/10.1073/pnas.0220537

24. Ewalt KL, Schimmel P (2002) Activation of angiongenic signaling pathways by two human tRNA synthetases. Biochemistry 41(45):13344–13349. https://doi.org/10.1021/bi020537k

25. Scott EM, Halees A, Itan Y, Spencer EG, He Y, Azab MA, Gabriel SB, Belkadi A, Boisson B, Abel L et al (2016) Characterization of Greater Middle Eastern genetic variation for enhanced disease gene discovery. Nat Genet 48(9):1071–1076. https://doi.org/10.1038/ng.3592

26. Fattahi Z, Beheshtian M, Mohseni M, Poustchi H, Sellars E, Nezhadhi SH, Amini A, Azrangi S, Jalalvand K, Jamali P et al (2019) Irame: a catalog of genomic variations in the Iranian population. Hum Mutat 40(11):1968–1984. https://doi.org/10.1002/humu.23880

27. Ward WH, Fersht AR (1988) Tyrosyl-tRNA synthetase acts as an asymmetric dimer in charging tRNA. A rationale for half-of-the-sites activity Biochemistry 27(15):5525–5530. https://doi.org/10.1021/bi00145a021

28. Jones DH, McMillan AJ, Fersht AR, Winter G (1985) Reversible dissociation of dimeric tyrosyl-tRNA synthetase by mutagenesis at the subunit interface. Biochemistry 24(21):5852–5857. https://doi.org/10.1021/bi00342a024

29. Yaremcuk A, Kriklivyi I, Tukalo M, Cusack S (2002) Class I tyrosyl-tRNA synthetase has a class II mode of cognate tRNA structure of an EMAP-II-like cytokine released from a human tRNA synthetase. Helv Chim Acta 86:1246–1257

30. Ittisophonisn S, Islam SA, Khanna T, Alhuzimi E, David A, Sternberg MJE (2019) Can predicted protein 3D Structures provide reliable insights into whether missense variants are disease associated? J Mol Biol 431(11):2197–2212. https://doi.org/10.1016/j.jmb.2019.04.009

31. Sayle RA, Milner-White EJ (1990) 3D-RASMDL: biomolecular graphics for all. Trends Biochem Sci 20(9):374. https://doi.org/10.1016/S0968-0004(00)89908-5

32. UniProt C (2019) UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res 47(D1):D506–D515. https://doi.org/10.1093/nar/gky1049

33. Baugh EH, Simmons-Edler R, Muller CL, Alford RF, Volfovsky N, Lash AE, Bonneau R (2016) Robust classification of protein variation using structural modelling and large-scale data integration. Nucleic Acids Res 44(6):2501–2513. https://doi.org/10.1093/nar/gkw120
39. Wakasugi K, Quinn CL, Tao N, Schimmel P (1998) Genetic code in evolution: switching species-specific aminocytlation with a peptide transplant. EMBO J 17(1):297–305. https://doi.org/10.1093/emboj/17.1.297

40. Park SG, Choi EC, Kim S (2010) Aminocytlation with multiple roles for truncated proteins: a triad for cellular homeostasis. IUBMB Life 62(4):296–302. https://doi.org/10.1002/iub.324

41. Accogli A, Russell L, Sebire G, Riviere JB, St-Onge J, Addour-Boudrahem N, Laporte AD, Rouleau GA, Saint-Martin C, Stour M (2019) Pathogenic variants in AIMP1 cause pontocerebellar hypoplasia. Neurogenetics 20(2):103–108. https://doi.org/10.1007/s10048-019-00572-7

42. Iqbal Z, Puttman L, Musante L, Razzaz A, Zahoor MY, Hu H, Wienker TF, Garshasbi M, Fattahi Z, Gilissen C et al. (2016) Missense variants in AIMP1 gene are implicated in autosomal recessive intellectual disability without neurodegeneration. Eur J Hum Genet 24(3):392–399. https://doi.org/10.1038/ejhg.2015.148

43. Yang XL, Kapoor M, Otero FJ, Slikke BM, Tsutaka H, Frausto R, Bates A, Ewalt KL, Chéres DA, Schimmel P (2007) Gain-of-function mutational activation of human tRNA synthetase proctokin. Chem Biol 14(12):1323–1333. https://doi.org/10.1016/j.chembiol.2007.10.016

44. Orenstein N, Weiss K, Oprescu SN, Sharipa R, Kidron D, Vanagaitė-Basel L, Antonellis A, Muenke M (2017) Bi-allelic IARS mutations in a child with intrauterine growth retardation, neonatal cholestasis and mild developmental delay. Clin Genet 91(6):913–917. https://doi.org/10.1111/cge.12930

45. Kopajtich R, Murayama K, Janecke AR, Haack TB, Breuer M, Knisely AS, Haring I, Ohashi T, Okazaki Y, Watanabe D et al (2016) Biallelic IARS mutations cause growth retardation with prenatal onset intellectual disability without muscle hypotonia and infantile hepatothropy. Am J Hum Genet 99(2):414–422. https://doi.org/10.1016/j.ajhg.2016.05.027

46. Hachhout A, Wieland T, Griese M, Baruffini E, Lorenz-Depiereux B, Einau L, Graf E, Dubus JC, Haliou-Louhaichi S, Coulomb A et al (2015) Biallelic mutations of methionyl-tRNA synthetase cause a specific type of pulmonary alveolar proteinosis prevalent on Reunion island. Am J Hum Genet 96(5):826–831. https://doi.org/10.1016/j.ajhg.2015.03.010

47. Casey JP, Slattery S, Cotter M, Monavari AA, Knerr I, Hughes J, Treacy EP, Devaney D, McDermott M, Laffan E et al (2015) Clinical and genetic characterisation of infantile liver failure syndrome type 1 due to recessive mutations in LARS. J Inherit Metab Dis 38(6):1085–1092. https://doi.org/10.1016/j.jimd.2015.09.012

48. Sun Y, Hu G, Luo J, Yang D, Yu Y, Wang X, Chen J, Qiu W (2017) Mutations in methionyl-tRNA synthetase gene in a Chinese family with interstitial lung and liver disease postnatal growth failure and anemia. J Hum Genet 62(6):647–651. https://doi.org/10.1038/jhg.2017.10

49. van Meel E, Wegner DJ, Clifton P, Willing MC, White FV, Kornfield S, Cole FS (2013) Rare recessive loss-of-function methionyl-tRNA synthetase mutations presenting as a multi-organ phenotype. BMC Med Genet 14:106. https://doi.org/10.1186/1471-2350-14-106

50. Lo WS, Gardiner E, Xu Z, Lau CF, Wang F, Zhou JJ, Mendlein JD, Nangle LA, Chiang KP, Yang XL et al (2014) Human tRNA synthetase catalytic nulls with diverse functions. Science 345(6194):328–332. https://doi.org/10.1126/science.1252943

51. Frolich CA, First EA (2011) Dominant intermediate Charcot-Marie-Tooth disorder is not due to a catalytic defect in tyrosyl-tRNA synthetase. Biochemistry 50(33):7132–7145. https://doi.org/10.1021/bi100989h

52. Bervoets S, Wei N, Erfurth ML, Yusein-Mashkova S, Ermanoska B, Mateiu L, Asselbergh B, Blochdel Q, Kakad P, Penserga T et al (2019) Transcriptional dysregulation by a nucleus-localized aminoacyl-tRNA synthetase associated with Charcot-Marie-Tooth neuropathy. Nat Commun 10(1):5045. https://doi.org/10.1038/s41467-019-12909-9

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Luisa Averdunk1,2 · Heinrich Sticht3 · Harald Surowy1 · Hermann-Josef Lüdecke1 · Margarete Koch-Hogrebe4 · Hessa S. Alsaiif5 · Kimia Kahrizi6 · Hamad Alzaibani5 · Bashayer S. Alawam5 · Mohamed Tohary5 · Cornelia Kraus7 · Luisa Averdunk1,2 · Heinrich Sticht3 · Harald Surowy1 · Hermann-Josef Lüdecke1 · Margarete Koch-Hogrebe4 · Hessa S. Alsaiif5 · Kimia Kahrizi6 · Hamad Alzaibani5 · Bashayer S. Alawam5 · Mohamed Tohary5 · Cornelia Kraus7 · Sabine Endele7 · Erin Wadman8 · Julie D. Kaplan8 · Stephanie Efthymiou9 · Hossein Najmabadi5 · André Reis7 · Fowzan S. Alkuraya5 · Dagmar Wieczorek1

1 Institute of Human Genetics, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Universitätsstraße 1, 40225 Düsseldorf, Germany
2 Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany
3 Division of Bioinformatics, Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
4 Children’s Hospital Datteln, University Witten Herdecke, Datteln, Germany
5 Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
6 Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
7 Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
8 Division of Medical Genetics, Department of Pediatrics, Nemours Alfred I, DuPont Hospital for Children, Wilmington, Delaware, DE, USA
9 Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK